Clinical trials: Skin Infections, Bacterial
Acute Bacterial Skin and Skin Structure Infection (ABSSSI), Prosthetic Joints Infection (PJI)
Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants
This is a phase 1, single-center, randomized, double-blind, placebo-controlled, dose-escalation clinical trial of single and multiple intravenous doses of TNP-2092 for injection in healthy Chinese participants.
- Trial name
- NCT06394518
- Testing
- TNP-2092 for injection
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- TenNor Therapeutics Inc.
Rheumatic Arthritis
Efficacy of Physiotherapy on the Health and Quality of Life of the Rheumatic Patient
Despite leading cause of morbidity, treatment strategies for Rheumatic diseases are geared almost exclusively toward medical-pharmacological area away from offering the patient the possibility of an interdisciplinary approach to…
- Trial name
- NCT02020668
- Testing
- Physiotherapy, Wait list control
- Where
- India
- Volunteers
- 82 people
- Sponsor
- Macmillan Research Group UK
Tinea Pedis, Athlete's Foot
Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis
This is a study of the safety and efficacy of Econazole Nitrate Foam 1% and the Foam Vehicle in subjects with interdigital tinea pedis (athlete's foot between the toes).
- Trial name
- NCT01358240
- Testing
- Econazole Nitrate Foam 1%, Vehicle Foam, Econazole Nitrate Cream 1%
- Where
- 12 sites in United States
- Volunteers
- 336 people
- Sponsor
- AmDerma
Skin Diseases, Bacterial
Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection
The purpose of this study was to evaluate the safety and tolerability of two 1200 milligram (mg) intravenous (IV) infusions of oritavancin when administered one week apart.
- Trial name
- NCT02925416
- Testing
- Oritavancin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- The Medicines Company
Hidradenitis Suppurativa
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NCT06799000
- Testing
- Remibrutinib Dose A, Remibrutinib Dose B
- Where
- 139 sites in United States, Argentina and 18 more
- Volunteers
- 588 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
The purpose of this study is to learn about the safety and effects of the study medicine (called Ritlecitinib) for the possible treatment of hidradenitis suppurativa (HS).
- Trial name
- NCT07228390
- Testing
- Ritlecitinib
- Where
- 60 sites in United States, Canada and 4 more
- Volunteers
- 128 people
- Sponsor
- Pfizer
Hidradenitis Suppurativa (HS)
Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SCT650C in patients with Moderate to Severe Hidradenitis Suppurativa
- Trial name
- NCT07244510
- Testing
- SCT650C
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Sinocelltech Ltd.
Tinea Cruris
Topical Antifungal Treatment for Tinea Cruris
To determine if a topical antifungal cream is safe and effective for the treatment of tinea cruris
- Trial name
- NCT01342315
- Testing
- 33525
- Where
- 21 sites in United States, Belize and 3 more
- Volunteers
- 483 people
- Sponsor
- Medicis Global Service Corporation
Staphylococcal Skin Infection
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Study 0018 (NCT00107978) compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
- Trial name
- ATLAS2 (NCT00107978)
- Testing
- Telavancin, Vancomycin
- Where
- United States
- Volunteers
- 1,035 people
- Sponsor
- Cumberland Pharmaceuticals
Onychomycosis
A Retrospective Analysis of the Effects of Low Level Laser Therapy on Toenail Onychomycosis
The purpose of this study is to determine whether low level laser therapy (LLLT) using the Erchonia LUNULA device is effective in increasing clear nail in toenails with onychomycosis.
- Trial name
- NCT02588599
- Testing
- Erchonia LUNULA
- Volunteers
- 54 people
- Sponsor
- Erchonia Corporation
Onychomycosis
A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis
The study is designed to evaluate the Safety, Tolerability and Pharmacokinetics of ATB1651 in participants with mild to moderate onychomycosis.
- Trial name
- NCT05089409
- Testing
- ATB1651, 2 mg/mL, ATB1651, 5 mg/mL, ATB1651, 10 mg/mL
- Where
- New Zealand
- Volunteers
- 30 people
- Sponsor
- AmtixBio Co., Ltd.
Staphylococcus Aureus, Atopic Dermatitis
Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Atopic Dermatitis
Atopic dermatitis (AD) is the most common chronic inflammatory skin disorder, with a lifetime prevalence of 15-25% in children and 1-3% in adults worldwide.
- Trial name
- NCT05092464
- Testing
- Natural Lactic Acid-enriched Cream
- Volunteers
- 10 people
- Sponsor
- Microbio Co Ltd
Staphylococcal Skin Infections, Wounds and Injuries
A Study for Patients With Complicated Skin and Skin Structure Infections
Two Phase III trials to demonstrate the efficacy and safety of oritavancin in the treatment of complicated skin and skin structure infections (cSSSI) have been completed.
- Conditions
- Staphylococcal Skin Infections, Wounds and Injuries, Abscess, Cellulitis
- Trial name
- SIMPLIFI (NCT00514527)
- Testing
- oritavancin
- Where
- 66 sites in United States, Australia and 4 more
- Volunteers
- 294 people
- Sponsor
- Targanta Therapeutics Corporation
Onychomycosis
A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule
The purpose of this study is to determine whether albaconazole tablets and albaconazole capsules (single 400mg dose) act in the body in the same way over a period of time.
- Trial name
- NCT01039883
- Testing
- Albaconazole tablet 400mg, Albaconazole 100mg capsules, then albaconazole 400mg tablet
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Stiefel, a GSK Company
Impetigo
Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
This is multicenter, randomised, placebo controlled, parallel, blinded (double-blind for ozenoxacin versus placebo comparison and investigator blinded for retapamulin versus placebo comparison), superiority clinical study…
- Trial name
- NCT01397461
- Testing
- retapamulin 1% ointment, ozenoxacin 1% cream
- Where
- 19 sites in Germany, South Africa
- Volunteers
- 465 people
- Sponsor
- Ferrer Internacional S.A.
Wound Infection, Abscess
Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
The purpose of this Phase 3 trial is to evaluate the efficacy, safety, and tolerability of oritavancin in ABSSSIs, including those caused by MRSA and to evaluate the potential economic benefit of oritavancin administered as a…
- Conditions
- Wound Infection, Abscess, Systemic Inflammation, Cellulitis
- Trial name
- SOLO II (NCT01252732)
- Testing
- Single-Dose IV Oritavancin Diphosphate, IV Vancomycin
- Where
- United States
- Volunteers
- 1,019 people
- Sponsor
- Melinta Therapeutics, Inc.
Tuberculosis
Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old.
This is a randomized, blind, positive-controlled study to explore the skin test dosage of recombinant mycobacterium tuberculosis fusion protein ( EEC) in the population aged 18 to 65 years old , and to further evaluate the safety…
- Trial name
- NCT06305104
- Testing
- 2.5μg/ml EEC, 5μg/ml EEC, 5 unit（U） EC
- Where
- 6 sites in China
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Chengdu CoenBiotech Co., Ltd
Onychomycosis
Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis
Open label study to evaluate the efficacy of CURE-EX device in the treatment of onychomycosis.
- Trial name
- NCT02436291
- Testing
- CURE-EX device
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- MB Mazor Ltd.
Infections, Gram-Positive Bacterial, Abscess
Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. One of the ways to deal with this problem is to develop new drugs that can control these bacteria.
- Conditions
- Infections, Gram-Positive Bacterial, Abscess, Burns, Cellulitis
- Trial name
- FAST (NCT00061633)
- Testing
- Telavancin, Vancomycin or antistaphylococcal penicillin
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- Cumberland Pharmaceuticals
Hidradenitis Suppurativa
Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa
This study will investigate how well adalimumab works in people with hidradenitis suppurativa (HS) in the short and long term.
- Trial name
- NCT00918255
- Testing
- adalimumab
- Where
- 26 sites in United States, Denmark and 2 more
- Volunteers
- 154 people
- Sponsor
- Abbott